Abstract
Health technology assessments (HTAs) inform reimbursement decisions. International differences in HTA processes lead to international differences in patient access to new treatments. Using HTAs for nivolumab plus chemotherapy in first-line gastric cancer as an example, we quantified the variation in time to patient access and in the evaluation of benefits between different HTA agencies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
